{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T12:02:44Z","timestamp":1759838564638,"version":"build-2065373602"},"reference-count":55,"publisher":"Elsevier BV","issue":"27","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.vaccine.2020.02.048","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T18:07:08Z","timestamp":1588874828000},"page":"4236-4245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Persistence of bactericidal antibodies following primary and booster MenACWY-TT vaccination of toddlers: A review of clinical studies"],"prefix":"10.1016","volume":"38","author":[{"given":"Chris","family":"Webber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Peyrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Balmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lidia","family":"Serra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.02.048_b0005","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jadohealth.2016.04.012","article-title":"The global evolution of meningococcal epidemiology following the introduction of meningococcal vaccines","volume":"59","author":"Pelton","year":"2016","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.vaccine.2020.02.048_b0010","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3389\/fped.2018.00321","article-title":"Invasive meningococcal disease in the vaccine era","volume":"6","author":"Nadel","year":"2018","journal-title":"Front Pediatr"},{"key":"10.1016\/j.vaccine.2020.02.048_b0015","first-page":"E121","article-title":"Meningococcal disease in childhood: epidemiology, clinical features and prevention","volume":"56","author":"Bosis","year":"2015","journal-title":"J Prev Med Hyg"},{"key":"10.1016\/j.vaccine.2020.02.048_b0020","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1016\/j.vaccine.2019.04.020","article-title":"Case fatality rates of invasive meningococcal disease by serogroup and age: a systematic review and meta-analysis","volume":"37","author":"Wang","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.048_b0025","doi-asserted-by":"crossref","first-page":"103571","DOI":"10.1016\/j.micpath.2019.103571","article-title":"Global estimate of Neisseria meningitidis serogroups proportion in invasive meningococcal disease: a systematic review and meta-analysis","volume":"134","author":"Purmohamad","year":"2019","journal-title":"Microb Pathog"},{"key":"10.1016\/j.vaccine.2020.02.048_b0030","unstructured":"Menactra\u00ae (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine). Full Prescribing Information, Sanofi Pasteur Inc., Swiftwater, PA, 2018."},{"key":"10.1016\/j.vaccine.2020.02.048_b0035","unstructured":"Menveo (Meningococcal Group A, C, W-135 and Y Conjugate Vaccine). Summary of Product Characteristics, GSK Vaccines S.r.l., Siena, Italy, 2019."},{"key":"10.1016\/j.vaccine.2020.02.048_b0040","unstructured":"NIMENRIX (Meningococcal Group A, C, W-135 and Y Conjugate Vaccine). Summary of Product Characteristics, Pfizer Limited, Sandwich, Kent, UK, 2017."},{"key":"10.1016\/j.vaccine.2020.02.048_b0045","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1016\/j.vaccine.2011.03.043","article-title":"Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: an open, randomized controlled trial","volume":"29","author":"Vesikari","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.048_b0050","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.vaccine.2009.10.064","article-title":"A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children","volume":"28","author":"Knuf","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.048_b0055","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1016\/j.vaccine.2011.03.009","article-title":"An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix hexa is immunogenic, with an acceptable safety profile in 12\u201323-month-old children","volume":"29","author":"Knuf","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.048_b0060","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1080\/21645515.2015.1136040","article-title":"Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants","volume":"12","author":"Baxter","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.02.048_b0065","unstructured":"Centers for Disease Control and Prevention. Chapter 14: Meningococcal disease, Public Health Foundation, https:\/\/www.cdc.gov\/vaccines\/pubs\/pinkbook\/downloads\/mening.pdf; 2015 [accessed January 28, 2020]."},{"key":"10.1016\/j.vaccine.2020.02.048_b0070","doi-asserted-by":"crossref","first-page":"e20162193","DOI":"10.1542\/peds.2016-2193","article-title":"Effectiveness and duration of protection of one dose of a meningococcal conjugate vaccine","volume":"139","author":"Cohn","year":"2017","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2020.02.048_b0075","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.1016\/j.vaccine.2019.06.076","article-title":"Antibody persistence and booster response following MenACWY-CRM vaccination in children as assessed by two different assay methods","volume":"37","author":"Klein","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.048_b0080","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1016\/j.vaccine.2018.04.064","article-title":"Antibody persistence and booster response 68 months after vaccination at 2\u201310 years of age with one dose of MenACWY-TT conjugate vaccine","volume":"36","author":"Knuf","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.048_b0085","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1080\/21645515.2016.1248009","article-title":"Antibody persistence up to 5 y after vaccination with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in adolescents","volume":"13","author":"Quiambao","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.02.048_b0090","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1186\/s12879-015-1138-y","article-title":"Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial","volume":"15","author":"Borja-Tabora","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2020.02.048_b0095","doi-asserted-by":"crossref","first-page":"e298","DOI":"10.1097\/INF.0000000000000897","volume":"34","author":"Vesikari","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2020.02.048_b0100","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.4161\/hv.22166","article-title":"Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers","volume":"8","author":"Vesikari","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.02.048_b0105","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/21645515.2015.1058457","article-title":"Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine","volume":"12","author":"Vesikari","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.02.048_b0110","doi-asserted-by":"crossref","first-page":"866","DOI":"10.4161\/hv.20229","article-title":"Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children","volume":"8","author":"Knuf","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.02.048_b0115","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/INF.0b013e31828693c5","article-title":"One or two doses of quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine is immunogenic in 9- to 12-month-old children","volume":"32","author":"Klein","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2020.02.048_b0120","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/INF.0000000000001123","article-title":"Five-year antibody persistence and booster response after 1 or 2 doses of meningococcal A, C, W and Y tetanus toxoid conjugate vaccine in healthy children","volume":"35","author":"Klein","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2020.02.048_b0125","unstructured":"ClinicalTrials.gov. Persistence of Antibodies After Meningococcal Vaccine PF-06866681 in Healthy Children (NCT01900899), https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01900899; 2019 [accessed September 26, 2019]."},{"key":"10.1016\/j.vaccine.2020.02.048_b0130","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.4161\/hv.22165","article-title":"A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2\u201310 years","volume":"8","author":"Vesikari","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.02.048_b0135","unstructured":"European Centre for Disease Prevention and Control. Vaccine Scheduler, https:\/\/vaccine-schedule.ecdc.europa.eu\/; 2018 [accessed November 12, 2019]."},{"key":"10.1016\/j.vaccine.2020.02.048_b0140","unstructured":"Public Health Agency of Canada. Canada\u2019s Provincial and Territorial Routine (and Catch-up) Vaccination Routine Schedule Programs for Infants and Children, https:\/\/www.canada.ca\/content\/dam\/phac-aspc\/documents\/services\/provincial-territorial-immunization-information\/ENG_Childhood_%20Schedule_August2019.pdf; 2019 [accessed September 25, 2019]."},{"key":"10.1016\/j.vaccine.2020.02.048_b0145","unstructured":"Australian Government Department of Health. National Immunisation Program Schedule, 1 April 2019, https:\/\/www.health.gov.au\/health-topics\/immunisation\/immunisation-throughout-life\/national-immunisation-program-schedule; 2019 [accessed September 25, 2019]."},{"key":"10.1016\/j.vaccine.2020.02.048_b0150","unstructured":"European Centre for Disease Prevention and Control. Surveillance Atlas of Infectious Diseases, https:\/\/ecdc.europa.eu\/en\/surveillance-atlas-infectious-diseases; 2017 [accessed September 4, 2019]."},{"key":"10.1016\/j.vaccine.2020.02.048_b0155","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.vaccine.2011.10.068","article-title":"Correlation between serum bactericidal activity against Neisseria meningitidis serogroups A, C, W-135 and Y measured using human versus rabbit serum as the complement source","volume":"30","author":"Gill","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.048_b0160","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1128\/CDLI.8.3.616-623.2001","article-title":"Importance of complement source in measuring meningococcal bactericidal titers","volume":"8","author":"Santos","year":"2001","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2020.02.048_b0165","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s12325-013-0032-5","article-title":"Immunogenicity and safety of a meningococcal serogroup A, C, Y and W glycoconjugate vaccine, ACWY-TT","volume":"30","author":"Findlow","year":"2013","journal-title":"Adv Ther"},{"key":"10.1016\/j.vaccine.2020.02.048_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2014.02.025","article-title":"Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents","volume":"164","author":"Baxter","year":"2014","journal-title":"J Pediatr"},{"issue":"suppl 5","key":"10.1016\/j.vaccine.2020.02.048_b0175","doi-asserted-by":"crossref","first-page":"S554","DOI":"10.1093\/cid\/civ504","article-title":"Human complement bactericidal responses to a group A meningococcal conjugate vaccine in Africans and comparison to responses measured by 2 other group A immunoassays","volume":"61","author":"Price","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2020.02.048_b0180","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.vaccine.2019.01.008","article-title":"Persistence of bactericidal antibodies 4 years after a booster dose of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MenACWY-D)","volume":"37","author":"Robertson","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.048_b0185","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/INF.0000000000002334","article-title":"Immunogenicity and safety of a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine 6 years after MenC priming as toddlers","volume":"38","author":"Nolan","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2020.02.048_b0190","first-page":"1","article-title":"Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"62","author":"Cohn","year":"2013","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2020.02.048_b0195","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1093\/cid\/ciu597","article-title":"The impact of the meningococcal serogroup C conjugate vaccine in Canada between 2002 and 2012","volume":"59","author":"Sadarangani","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2020.02.048_b0200","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1080\/21645515.2018.1532248","article-title":"Recent changes in the epidemiology of Neisseria meningitidis serogroup W across the world, current vaccination policy choices and possible future strategies","volume":"15","author":"Booy","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.02.048_b0205","unstructured":"Ministerio de Salud (Gobierno de Chile). Vaccination Calendar 2017, http:\/\/vacunas.minsal.cl\/calendario-de-vacunacion-2017\/; 2017 [accessed May 30, 2019]."},{"key":"10.1016\/j.vaccine.2020.02.048_b0210","doi-asserted-by":"crossref","first-page":"6915","DOI":"10.1016\/j.vaccine.2019.09.050","article-title":"Meningococcal invasive disease by serogroup W and use of ACWY conjugate vaccines as control strategy in Chile","volume":"37","author":"Villena","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.048_b0215","doi-asserted-by":"crossref","first-page":"776","DOI":"10.4067\/S0034-98872019000600776","article-title":"National action plan for the emergence of strain W-135 responsible for invasive meningococcal disease in Chile, 2012\u20132013","volume":"147","author":"Valenzuela","year":"2019","journal-title":"Rev Med Chile"},{"key":"10.1016\/j.vaccine.2020.02.048_b0220","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2018.23.16.18-00158","article-title":"Implementation of MenACWY vaccination because of ongoing increase in serogroup W invasive meningococcal disease, the Netherlands, 2018","volume":"23","author":"Knol","year":"2018","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2020.02.048_b0225","unstructured":"Ministerie van Volksgezondheid Welzijn en Sport. MenACWY-vaccin vervangt MenC-vaccin, https:\/\/rijksvaccinatieprogramma.nl\/nieuwsbrieven\/april-2018; 2018 [accessed January 28, 2020]."},{"key":"10.1016\/j.vaccine.2020.02.048_b0230","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1016\/j.vaccine.2017.06.007","article-title":"Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: optimal age for vaccination","volume":"35","author":"van Ravenhorst","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.048_b0235","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1016\/j.vaccine.2017.06.053","article-title":"Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: a randomized controlled trial","volume":"35","author":"van Ravenhorst","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.048_b0240","unstructured":"National Centre for Immunisation Research & Surveillance. Fact sheet: meningococcal vaccines, http:\/\/ncirs.org.au\/sites\/default\/files\/2019-04\/Meningococcal_FactSheet_April2019_Final.pdf; 2018 [accessed January 28, 2020]."},{"key":"10.1016\/j.vaccine.2020.02.048_b0245","unstructured":"Hunt G. National action plan to improve the health of children and young people, Liberal Party of Australia, https:\/\/www.liberal.org.au\/latest-news\/2019\/05\/08\/national-action-plan-improve-health-children-and-young-people#lpa-central-content; 2019 [accessed January 28, 2020]."},{"key":"10.1016\/j.vaccine.2020.02.048_b0250","unstructured":"World Health Organization. WHO vaccine-preventable diseases: monitoring system. 2019 global summary, http:\/\/apps.who.int\/immunization_monitoring\/globalsummary\/schedules; 2019 [accessed January 28, 2020]."},{"key":"10.1016\/j.vaccine.2020.02.048_b0255","unstructured":"Superior Health Council Belgium. Advisory 9485 meningococcal vaccination, https:\/\/www.health.belgium.be\/nl\/advies-9485-vaccinatie-tegen-meningokokken; 2019 [accessed January 28, 2020]."},{"issue":"suppl 2","key":"10.1016\/j.vaccine.2020.02.048_b0260","doi-asserted-by":"crossref","first-page":"B63","DOI":"10.1016\/j.vaccine.2011.12.063","article-title":"Can we defeat meningococcal disease in low and middle income countries?","volume":"30","author":"Greenwood","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.048_b0265","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.smim.2013.05.004","article-title":"Vaccines for low-income countries","volume":"25","author":"MacLennan","year":"2013","journal-title":"Semin Immunol"},{"key":"10.1016\/j.vaccine.2020.02.048_b0270","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1016\/j.vaccine.2018.02.013","article-title":"Immunogenicity and safety of one or two doses of the quadrivalent meningococcal vaccine MenACWY-TT given alone or with the 13-valent pneumococcal conjugate vaccine in toddlers: a phase III, open-label, randomised study","volume":"36","author":"Cutland","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.02.048_b0275","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2217\/fmb-2018-0343","article-title":"Immunogenicity and safety of meningococcal group A, C, W and Y tetanus toxoid conjugate vaccine: review of clinical and real-world evidence","volume":"14","author":"Findlow","year":"2019","journal-title":"Future Microbiol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20302607?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20302607?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:43:06Z","timestamp":1759401786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20302607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":55,"journal-issue":{"issue":"27","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0264410X20302607"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.02.048","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Persistence of bactericidal antibodies following primary and booster MenACWY-TT vaccination of toddlers: A review of clinical studies","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.02.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}